✦ LIBER ✦

Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing–remitting multiple sclerosis in The Netherlands

✍ Scribed by Heisen, M.; Treur, M. J.; van der Hel, W. S.; Frequin, S. T. F. M.; Groot, M. T.; Verheggen, B. G.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PND33 Cost Minimization Analysis of Fing

✍ B. Verheggen; M. Treur; M. Groot 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Cost analysis of glatiramer acetate vs.

✍ Rainel Sanchez-de la Rosa, Eliazar Sabater, Miguel A Casado 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 206 KB

PND9 THE COST-EFFECTIVENESS OF NATALIZUM

✍ K Meyer; E Chiao 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Elevated melatonin levels in natalizumab

✍ Bahamonde, Carmen; Conde, Cristina; Agüera, Eduardo; Lillo, Rafael; Luque, Eveli 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 914 KB

PND30 Cost Analysis of Glatiramer Acetat

✍ Sánchez-de la Rosa, R.; Sabater, E.; Casado, M.A. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PND35 Belgian Cost-Utility Analysis of G

✍ S. Drieskens; K. Moeremans 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB